REFERENCES
1. Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003;58:249-65.
2. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013;202:329-35.
3. Laborde-Lahoz P, El-Gabalawy R, Kinley J, Kirwin PD, Sareen J, Pietrzak RH. Subsyndromal depression among older adults in the USA: prevalence, comorbidity, and risk for new-onset psychiatric disorders in late life. Int J Geriatr Psychiatry 2015;30:677-85.
4. Lenze EJ, Rogers JC, Martire LM, et al. The Association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research. The American Journal of Geriatric Psychiatry 2001;9:113-35.
5. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006;113:372-87.
6. WHO. Depression and other common mental disorders: global health estimates. heepsAvailable form: https://apps.who.int/iris/handle/10665/254610 [Last accessed on 25Mar 2022].
7. Lenze, EJ, Sheffrin M, Driscoll HC, et al. Incomplete response in late-life depression: getting to remission. Dialogues Clin Neurosci 2009;10:419-30.
8. Paroni G, Seripa D, Fontana A, et al. Klotho gene and selective serotonin reuptake inhibitors: response to treatment in late-life major depressive disorder. Mol Neurobiol 2017;54:1340-51.
9. Schaakxs R, Comijs HC, Lamers F, Kok RM, Beekman ATF, Penninx BWJH. Associations between age and the course of major depressive disorder: a 2-year longitudinal cohort study. The Lancet Psychiatry 2018;5:581-90.
10. Comijs HC, Nieuwesteeg J, Kok R, et al. The two-year course of late-life depression; results from the Netherlands study of depression in older persons. BMC Psychiatry 2015;15:20.
12. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. “Vascular depression” hypothesis. Arch Gen Psychiatry 1997;54:915-22.
14. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry 1997;154:497-501.
15. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006;67:16-22. Available from:
16. Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
17. Aizenstein HJ, Baskys A, Boldrini M, et al. Vascular depression consensus report - a critical update. BMC Med 2016;14:161.
18. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. The Lancet Neurology 2013;12:483-97.
19. Nestler EJ, Barrot M, Dileone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
20. Agtmaal MJM, Houben AJHM, Pouwer F, Stehouwer CDA, Schram MT. Association of microvascular dysfunction with late-life depression: a systematic review and meta-analysis. JAMA Psychiatry 2017;74:729-39.
21. Geraets AF, Köhler S, Jansen JF, et al. The association of markers of cerebral small vessel disease and brain atrophy with incidence and course of depressive symptoms - the maastricht study. J Affect Disord 2021;292:439-47.
22. van Sloten TT, Sigurdsson S, van Buchem MA, et al. Cerebral small vessel disease and association with higher incidence of depressive symptoms in a general elderly population: the ages-reykjavik study. Am J Psychiatry 2015;172:570-8.
23. Perez HC, Direk N, Hofman A, Vernooij MW, Tiemeier H, Ikram MA. Silent brain infarcts: a cause of depression in the elderly? Psychiatry Res 2013;211:180-2.
24. Houben AJHM, Martens RJH, Stehouwer CDA. Assessing microvascular function in humans from a chronic disease perspective. J Am Soc Nephrol 2017;28:3461-72.
25. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007;100:158-73.
26. . Hall, J.E. and A.C. Guyton, textbook of medical physiology. 2011. 12th edn: p. 157-66. ISBN:978-1-4160-4574-8.
27. Li W, Schram MT, Sörensen BM, et al. Microvascular phenotyping in the maastricht study: design and main findings, 2010-2018. Am J Epidemiol 2020;189:873-84.
28. van Sloten TT, Schram MT, Adriaanse MC, et al. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn study. Psychol Med 2014;44:1403-16.
29. van Dooren FE, Schram MT, Schalkwijk CG, et al. Associations of low grade inflammation and endothelial dysfunction with depression - the Maastricht study. Brain behav immun 2016;56:390-6.
30. Geraets AFJ, van Agtmaal MJM, Stehouwer CDA, et al. Association of markers of microvascular dysfunction with prevalent and incident depressive symptoms: the Maastricht study. Hypertension 2020;76:342-9.
31. Janssen EPCJ, Köhler S, Geraets AFJ, et al. Low-grade inflammation and endothelial dysfunction predict four-year risk and course of depressive symptoms: The Maastricht study. Brain Behav Immun 2021;97:61-7.
32. Massardo T, Quintana JC, Jaimovich R, et al. Regional brain perfusion is associated with endothelial dysfunction markers in major depressive disorder. Neuropsychobiology 2021;80:214-24.
33. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640-5.
35. Shu MJ, Zhai FF, Zhang DD, et al. Metabolic syndrome, intracranial arterial stenosis and cerebral small vessel disease in community-dwelling populations. Stroke Vasc Neurol 2021;6:589-94.
36. Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012;35:1171-80.
37. Takeuchi T, Nakao M, Nomura K, Yano E. Association of metabolic syndrome with depression and anxiety in Japanese men. Diabetes Metab 2009;35:32-6.
38. Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. Journal of Affective Disorders 2012;142:S8-S21.
39. Nefs G, Pouwer F, Denollet J, Pop V. The course of depressive symptoms in primary care patients with type 2 diabetes: results from the diabetes, depression, type D Personality Zuidoost-Brabant (DiaDDZoB) study. Diabetologia 2012;55:608-16.
40. Sloten T, Schram M. Understanding depression in type 2 diabetes: a biological approach in observational studies. F1000Res 2018;7:1283.
41. Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. The Lancet Neurology 2020;19:699-710.
42. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet Neurology 2013;12:822-38.
43. Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013;36:166-75.
44. Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem Res 2007;32:1749-56.
45. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010;197:372-7.
46. Tong A, Wang X, Li F, Xu F, Li Q, Zhang F. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol 2016;53:589-98.
47. Beran M, Muzambi R, Geraets A, et al. European Depression in Diabetes (EDID) Research Consortium. The bidirectional longitudinal association between depressive symptoms and HbA1c : a systematic review and meta-analysis. Diabet Med 2022;39:e14671.
48. Meurs M, Roest AM, Wolffenbuttel BH, Stolk RP, de Jonge P, Rosmalen JG. Association of depressive and anxiety disorders with diagnosed versus undiagnosed diabetes: an epidemiological study of 90,686 participants. Psychosom Med 2016;78:233-41.
49. Geraets AFJ, Köhler S, Muzambi R, et al. The association of hyperglycaemia and insulin resistance with incident depressive symptoms over 4 years of follow-up: The Maastricht Study. Diabetologia 2020;63:2315-28.
50. Janssen EP, Köhler S, Stehouwer CD, et al. The patient health questionnaire-9 as a screening tool for depression in individuals with type 2 diabetes mellitus: the Maastricht study. J Am Geriatr Soc 2016;64:e201-6.
51. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2013;150:736-44.
52. Copeland WE, Shanahan L, Worthman C, Angold A, Costelloet EJ. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry 2012;71:15-21.
53. Chocano-Bedoya PO, Mirzaei F, O’Reilly EJ, et al. C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression. J Affect Disord 2014;163:25-32.
54. Baune BT, Smith E, Reppermund S, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney memory and aging study. Psychoneuroendocrinology 2012;37:1521-30.
55. Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 2013;70:176-84.
56. Zalli A, Jovanova O, Hoogendijk WJ, Tiemeier H, Carvalho LA. Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology (Berl) 2016;233:1669-78.
57. van den Biggelaar AH, Gussekloo J, de Craen AJ, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol 2007;42:693-701.
58. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009;23:936-44.
59. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
60. Romeo HE, Tio DL, Rahman SU, Chiappelli F, Taylor AN. The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: relevance to neuroimmune surveillance of the oral cavity. Journal of Neuroimmunology 2001;115:91-100.
61. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C. Cytokine signals propagate through the brain. Mol Psychiatry 2000;5:604-15.
63. Schiltz JC, Sawchenko PE. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci 2002;22:5606-18.
64. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-17.
65. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:722-9.
66. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 2015;25:1532-43.
67. Baquero M, Martín N. Depressive symptoms in neurodegenerative diseases. World J Clin Cases 2015;3:682-93.
68. Burgut FT, Benaur M, Hencliffe C. Late-life depression: a neuropsychiatric approach. Expert Rev Neurother 2006;6:65-72.
69. Tittmann M, Günther T, Sacher J, et al. Structural brain changes in early-onset and late-onset depression: an update of volumetric MRI findings. Int J Imaging Syst Technol 2014;24:149-60.
70. Gudmundsson P, Olesen PJ, Simoni M, et al. White matter lesions and temporal lobe atrophy related to incidence of both dementia and major depression in 70-year-olds followed over 10 years. Eur J Neurol 2015;22:781-8, e49.
71. Cyprien F, Courtet P, Poulain V, et al. Corpus callosum size may predict late-life depression in women: a 10-year follow-up study. J Affect Disord 2014;165:16-23.
72. Almeida OP, Burton EJ, Ferrier N, McKeith IG, O'Brien JT. Depression with late onset is associated with right frontal lobe atrophy. Psychol Med 2003;33:675-81.
73. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
74. Disabato BM, Sheline YI. Biological basis of late life depression. Curr Psychiatry Rep 2012;14:273-9.
75. Scott KM. Prevention of CVD in depression. In: Baune BT, Tully PJ, editors. Cardiovascular Diseases and Depression. Cham: Springer International Publishing; 2016. p. 509-17.
76. Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013;8:e57058.
77. Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
78. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
79. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. American Heart Association Prevention Committee of the Council on Cardiovascular Nursing. , American Psychiatric Association. depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American psychiatric association. Circulation 2008;118:1768-75.
80. Stewart A, Driscoll A, Hare D. National survey of Australian cardiologists’ beliefs and practice regarding screening, diagnosis and management of depression. Heart, Lung and Circulation 2009;18:S5.
81. Young-Hyman D, Groot DM, Hill-Briggs F, et al. Psychosocial care for people with diabetes: a position statement of the American diabetes association. Diabetes Care 2016;39:2126-40.
82. Barents ESE, Bilo HJG, Bouma M, et al. Diabetes mellitus type 2. Available from: https://richtlijnen.nhg.org/standaarden/diabetes-mellitus-type-2 [Last accessed on 25 Mar 2022].
83. Trangle, M., J. Gursky, and R. Haight, Adult depression in primary care. ICSI Inst Clin Syst Improv. Available from: https://www.icsi.org/guideline/depression/ [Last accessed on 25 Mar 2022].
84. Stehouwer CDA. Microvascular Dysfunction and hyperglycemia: a vicious cycle with widespread consequences. Diabetes 2018;67:1729-41.
85. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-7.
86. Fluharty M, Taylor AE, Grabski M, Munafò MR. The association of cigarette smoking with depression and anxiety: a systematic review. Nicotine Tob Res 2017;19:3-13.
87. Trimbos-instituut.ADDENDUM OUDEREN BIJ DE MDR DEPRESSIE. Available from: https://www.trimbos.nl/docs/b0822cf7-b915-44a2-9a55-db6ea341267a.pdf [Last accessed on 25 Mar 2022].
88. Petrak F, Baumeister H, Skinner TC, Brown A, Holt RIG. Depression and diabetes: treatment and health-care delivery. The Lancet Diabetes & Endocrinology 2015;3:472-85.
89. Bennett S, Thomas AJ. Depression and dementia: cause, consequence or coincidence? Maturitas 2014;79:184-90.
90. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmer RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012;69:493-8.
91. Köhler S, Buntinx F, Palmer K, van den Akker M. Depression, vascular factors, and risk of dementia in primary care: a retrospective cohort study. J Am Geriatr Soc 2015;63:692-8.
92. Heintz H, Monette P, Epstein-Lubow G, Smith L, Rowlett S, Forester BP. Emerging collaborative care models for dementia care in the primary care setting: a narrative review. Am J Geriatr Psychiatry 2020;28:320-30.
